BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ibuzatrelvir readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ibuzatrelvir\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07013474-11275@assetmemo.bio
DTSTAMP:20261121T004111Z
DTSTART;VALUE=DATE:20270928
DTEND;VALUE=DATE:20270929
SUMMARY:Ibuzatrelvir: Phase 3 readout est. (NCT07013474)
DESCRIPTION:Ibuzatrelvir\, phase 3\, COVID-19.\nStudy: A Study to Learn Abo
 ut the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severel
 y Immunocompromised\nEstimated primary completion: 28 September 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/ibuzatrelvir#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07013474
URL:https://assetmemo.bio/drug/ibuzatrelvir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06679140-11275@assetmemo.bio
DTSTAMP:20261121T004111Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Ibuzatrelvir: Phase 3 readout est. (NCT06679140)
DESCRIPTION:Ibuzatrelvir\, phase 3\, COVID-19.\nStudy: A Study to Learn Abo
 ut a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients W
 ith COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease\n
 Estimated primary completion: 1 October 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ibuzatrelvir#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06679140
URL:https://assetmemo.bio/drug/ibuzatrelvir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
